InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: vinmantoo post# 1864

Tuesday, 04/28/2020 5:51:34 PM

Tuesday, April 28, 2020 5:51:34 PM

Post# of 3017
ENTA's FY2Q20 earnings will likely be soft for two reasons: 1) The Mavyret royalty rate drops to 10% at the beginning of each calendar year and has to work its way back to the higher tiers as the year progresses; and 2) ABBV's Mavyret sales to new patients presumably fell in March, when people started deferring non-essential doctor visits.

I still think ENTA is a strong buyout candidate, FWIW.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News